Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Tesla, Inc. — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Tesla, Inc. trades at $362.5 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 174.5× Hinge Health Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Tesla, Inc. for 88 Days on average.
| HNGE | TSLA | |
|---|---|---|
Market Cap | $8.48B | $1.48T |
Volume | 879,799 | 18,314,332 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $489.88 |
52-Week Low | $31.17 | $298.16 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $8.10B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Tesla (TSLA) trades at $367.16, down 2.88% on the day, amid mixed signals. The technical outlook is bullish based on moving averages, but oscillators are neutral. Recent earnings showed a Q2 2026 miss after two prior beats. Revenue declined slightly in 2025 to $94.83B, with net income margin compressing to 4%. The company maintains a strong balance sheet with $36.56B in cash, though valuation ratios like a P/E of 347.44 remain elevated. News highlights focus on autonomous driving approvals in Europe and a potential cheaper EV model.
Tesla's investment case balances high growth expectations in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441.36 implies upside, but investors face risks from competitive pressures, volatile earnings, and the stock's sensitivity to sentiment shifts around its AI and robotics initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
